RMD Open
is an open access, peer-reviewed rheumatology journal that publishes original research on rheumatic and musculoskeletal disorders and connective tissue diseases
Impact Factor: 5.1
Citescore: 7.3
All metrics >>
Authors
RMD Open accepts submissions of a wide range of article types, including original research, analysis and practice articles, and commentaries.
The Author Information section provides specific article requirements to help you turn your work into an article suitable for RMD Open.
Information is also provided on editorial policies and open access.
Latest Articles
Epidemiology:
Trends and influences in women authorship in randomised controlled trials in rheumatology: a comprehensive analysis of all published RCTs from 2009 to 202327 March 2025
Education:
Social media in advancing equity and collaboration in rheumatology: the CORDIALITY review27 March 2025
Correction:
Correction: experimental myositis: an optimised version of C-protein-induced myositis26 March 2025
Systemic sclerosis:
Immunoglobulins G from Patients with Systemic Sclerosis Modify the Molecular Signatures of Endothelial Cells23 March 2025
Rheumatoid arthritis:
Infliximab use and cervical spine deformity in patients with rheumatoid arthritis18 March 2025
Virtual Collection: Basic and Translational Research
Read the new virtual collection highlighting basic and translational research on the topic of 'Molecular patient stratification and pathogenic cell activation' curated by RMD Open Associate Editor, Caroline Ospelt.
RMD Open welcomes the submission of high quality basic and translational studies utilizing advanced, innovative analysis methods to further elucidate basic mechanisms of cell activation and disease heterogeneity in RMDs.
Altmetrics
Most Read Articles
Pain:
Long versus short-term opioid therapy for fibromyalgia syndrome and risk of depression, sleep disorders and suicidal ideation: a population-based, propensity-weighted cohort study23 September 2024
Lupus:
Recommendations for physical activity and exercise in persons living with Systemic Lupus Erythematosus (SLE): consensus by an international task force4 April 2024
Rheumatoid arthritis:
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study28 May 2024
Spine:
Cryoneurolysis versus radiofrequency ablation outcome on pain experience in chronic low back pain (COPE): a single-blinded randomised controlled trial9 May 2024
Osteoarthritis:
Twenty-year trajectories of morbidity in individuals with and without osteoarthritis2 July 2024